Monte Rosa, BioAge plunge after Novo’s setback (GLUE:NASDAQ)
· seekingalpha.com
Novo Nordisk’s (NVO) trial failure for the heart drug raises doubts on anti-inflammatory drugs developed by Monte Rosa (GLUE) and BioAge Labs (BIOA). Read more here.
Shares of Monte Rosa Therapeutics (GLUE) and BioAge Labs (BIOA) fell sharply on Friday after a late-stage trial setback for Novo Nordisk (NVO) called into quest...